Pyrin Inflammasome Activation Defines Colchicine-Responsive SURF Patients from FMF and Other Recurrent Fevers
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Syndrome of undifferentiated recurrent fever (SURF) is characterized by recurrent fevers, a lack of confirmed molecular diagnosis, and a complete or partial response to colchicine. Despite the clinical similarities to familial Mediterranean fever (FMF), the underlying inflammatory mechanisms of SURF are not yet understood. We here analyzed the in vitro activation of the pyrin inflammasome in a cohort of SURF patients compared to FMF and PFAPA patients. Peripheral blood mononuclear cells (PBMC) were collected from SURF (both colchicine-treated and untreated), FMF, PFAPA patients, and healthy donors. PBMC were stimulated ex vivo with Clostridium difficile toxin A (TcdA) and a PKC inhibitor (UCN-01), in the presence or absence of colchicine. The assembly of the pyrin inflammasome was evaluated by measuring the presence of apoptosis-associated Speck-like protein containing caspase recruitment domain (ASC) specks in monocytes using flow cytometry. IL-1β secretion was quantified using an ELISA assay. No differences in TcdA-induced activation of pyrin inflammasome were observed among FMF, PFAPA, and healthy donors. Untreated SURF patients showed a reduced response to TcdA, which was normalized after colchicine treatment. In contrast to FMF, SURF patients, similar to PFAPA patients and healthy donors, did not exhibit pyrin inflammasome activation in response to UCN-01-mediated pyrin dephosphorylation. These data demonstrate that in vitro functional analysis of pyrin inflammasome activation can differentiate SURF from FMF and PFAPA patients, suggesting the involvement of the pyrin inflammasome in the pathophysiology of SURF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Journal of clinical immunology - 44(2024), 2 vom: 17. Jan., Seite 49 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Palmeri, Serena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Colchicine |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 19.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10875-023-01649-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367219085 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367219085 | ||
| 003 | DE-627 | ||
| 005 | 20240219232004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10875-023-01649-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1299.xml |
| 035 | |a (DE-627)NLM367219085 | ||
| 035 | |a (NLM)38231350 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Palmeri, Serena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pyrin Inflammasome Activation Defines Colchicine-Responsive SURF Patients from FMF and Other Recurrent Fevers |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 19.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Syndrome of undifferentiated recurrent fever (SURF) is characterized by recurrent fevers, a lack of confirmed molecular diagnosis, and a complete or partial response to colchicine. Despite the clinical similarities to familial Mediterranean fever (FMF), the underlying inflammatory mechanisms of SURF are not yet understood. We here analyzed the in vitro activation of the pyrin inflammasome in a cohort of SURF patients compared to FMF and PFAPA patients. Peripheral blood mononuclear cells (PBMC) were collected from SURF (both colchicine-treated and untreated), FMF, PFAPA patients, and healthy donors. PBMC were stimulated ex vivo with Clostridium difficile toxin A (TcdA) and a PKC inhibitor (UCN-01), in the presence or absence of colchicine. The assembly of the pyrin inflammasome was evaluated by measuring the presence of apoptosis-associated Speck-like protein containing caspase recruitment domain (ASC) specks in monocytes using flow cytometry. IL-1β secretion was quantified using an ELISA assay. No differences in TcdA-induced activation of pyrin inflammasome were observed among FMF, PFAPA, and healthy donors. Untreated SURF patients showed a reduced response to TcdA, which was normalized after colchicine treatment. In contrast to FMF, SURF patients, similar to PFAPA patients and healthy donors, did not exhibit pyrin inflammasome activation in response to UCN-01-mediated pyrin dephosphorylation. These data demonstrate that in vitro functional analysis of pyrin inflammasome activation can differentiate SURF from FMF and PFAPA patients, suggesting the involvement of the pyrin inflammasome in the pathophysiology of SURF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Colchicine | |
| 650 | 4 | |a Familial Mediterranean fever | |
| 650 | 4 | |a Inflammasomes | |
| 650 | 4 | |a Monogenic autoinflammatory diseases | |
| 650 | 4 | |a Pyrin | |
| 650 | 4 | |a SURF | |
| 650 | 4 | |a Undifferentiated recurrent fevers | |
| 650 | 7 | |a Colchicine |2 NLM | |
| 650 | 7 | |a SML2Y3J35T |2 NLM | |
| 650 | 7 | |a Inflammasomes |2 NLM | |
| 650 | 7 | |a Pyrin |2 NLM | |
| 700 | 1 | |a Penco, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoni, Arinna |e verfasserin |4 aut | |
| 700 | 1 | |a Bustaffa, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Matucci-Cerinic, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Papa, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Drago, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Caorsi, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Corcione, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Bocca, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Scarone, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Rubartelli, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Volpi, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Gattorno, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Prigione, Ignazia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical immunology |d 1981 |g 44(2024), 2 vom: 17. Jan., Seite 49 |w (DE-627)NLM012677426 |x 1573-2592 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:2 |g day:17 |g month:01 |g pages:49 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10875-023-01649-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 2 |b 17 |c 01 |h 49 | ||